Gossamer Bio is trading 10.35% down at $10.48 on September 23, 2026, as rising crude prices renew inflation concerns and weigh on equity valuations. - U.S. markets are lower, with the 10-year Treasury yield pushed toward 4.99%. - No clear company-specific announcement or catalyst dated September 23 was identified. - The decline appears primarily macro-driven; biotechnology is outperforming, limiting sector-specific support.